Logo image
Oropharyngeal Candidiasis in Patients with AIDS: Randomized Comparison of Fluconazole Versus Nystatin Oral Suspensions
Journal article   Peer reviewed

Oropharyngeal Candidiasis in Patients with AIDS: Randomized Comparison of Fluconazole Versus Nystatin Oral Suspensions

Vincent Pons, Deborah Greenspan, Francina Lozada-Nur, Laurie McPhail, Joel E. Gallant, Allan Tunkel, Caroline C. Johnson, James McCarty, Helene Panzer, Marcia Levenstein, …
Clinical infectious diseases, v 24(6), pp 1204-1207
Jun 1997
PMID: 9195083

Abstract

A total of 167 human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis were randomly assigned to receive 14 days of therapy with liquid suspension fluconazole (100 mg once daily) or liquid nystatin (500,000 U four times daily). At day 14, 87% of the fluconazole-treated patients were clinically cured, as opposed to 52% in the nystatin-treated group (P < .001). Fluconazole eradicated Candida organisms from the oral flora in 60%, vs. a 6% eradication rate with nystatin (P < .001). The fluconazole group had fewer relapses noted on day 28 (18%, vs. 44% in the nystatin group; P < .001). This relapse difference no longer existed by day 42. Fluconazole oral suspension as a systemic therapy was more effective than liquid nystatin as a topical therapy in the treatment of oral candidiasis in HIV-infected patients and provided a longer disease-free interval before relapse.

Metrics

18 Record Views
87 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Immunology
Infectious Diseases
Microbiology
Logo image